前收市價 | 1.2400 |
開市 | 1.2200 |
買盤 | 1.1800 x 100 |
賣出價 | 1.2400 x 100 |
今日波幅 | 1.2000 - 1.2300 |
52 週波幅 | 0.5750 - 1.7900 |
成交量 | |
平均成交量 | 351,887 |
市值 | 75.166M |
Beta 值 (5 年,每月) | 1.29 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -1.8600 |
業績公佈日 | 2024年5月09日 - 2024年5月13日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 7.00 |
Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Stay on the Internet long enough – and it won’t take too long, believe me – and you’ll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns to outright conspiracy theories, the suits on Wall Street don’t always get the love from retail investors. Plus, they tend to be conservative for good reason. You don’t want to destroy your reputation by endorsing junk securities. That said, we’re all human. And humans love every now and then to specul
Playing in the field of nano-cap stocks is similar to the concept of stealing bases. In a tight baseball game, every advantage counts. Therefore, you might get the signal from the manager to steal a bag. You could end up being the hero or end up looking like a fool. It’s a binary proposition: high risk, high reward. And while advantages help break up a tight game, you also don’t want to give up cheap outs. That could put you in a serious disadvantage. And that’s why people seldom invest heavily